Navigation Links
Src Inhibitors in Breast Cancer Therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha .

These ER-alphanegative cancers are more aggressive and have a worse prognosis than do ER-alphapositive breast cancers, and have been thought to be estrogen independent.

In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Joyce Slingerland and colleagues from the University of Miami shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.

In their study of 250 primary breast cancers, the authors found that ER mRNA levels overlap considerably between ER-alphapositive and ER-alphanegative breast cancers.

This lack of correlation between ER-alpha mRNA and protein levels pointed to the existence of important post-transcriptional control of ER-alpha expression.

They found that ER-alphanegative primary breast cancers and cell lines showed increased levels and/or activity of the protein Src, which cooperates with estrogen to activate ER-alpha breakdown via proteolysis.

In line with this finding, Src inhibition was shown to impair estrogen-stimulated ER-alpha proteolysis. The data raise the possibility that for at least a subset of ER-alphanegative breast cancers, Src may stimulate estrogen-dependent ER-alpha degradation, resulting in a lack of ER-alpha detection, and more aggressive tumor growth.

The authors conclude that their study provides a rationale for the use of Src inhibitors in breast cancer therapy.

AUTHOR CONTACT: Joyce M. Slingerland University of Miami Miller School of Medicine, Miami, Florida, USA. Phone : (305) 243-7265; Fax: (305) 243-4787; E-mail:


Page: 1

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. LipB Protein Inhibitors Help To Fight Against TB
3. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
4. ACE Inhibitors For Vascular Disease Patients
5. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
6. Consensus on "Combination Therapy" for Breast Cancer
7. Breast cancer treatment to be determined by gene test
8. Breast Feeding prevents obesity later on in life
9. Breast milk is essential
10. Breast Cancer Surgery Causes Psychological problems
11. Breast cancer evidence
Post Your Comments:

(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
(Date:11/24/2015)... ... 24, 2015 , ... Autism Speaks, the world’s leading autism science and advocacy ... and the generosity of people around the world. On December 1, supporters can make ... – and share the personal stories behind those gifts. , Just as Black ...
(Date:11/24/2015)... Geneva, IL (PRWEB) , ... November 24, 2015 , ... All her life, Don Peck’s ... Even her obituary said she might have been. After a 25-year search for ... Mayflower voyager with whom she shared a last name. Turns out, it was Don’s ...
(Date:11/24/2015)... Pass, OR (PRWEB) , ... November 24, 2015 , ... ... Lose too much body water to perspiration in the hot sun, and heat stroke ... to Fresh water advocate and radio host Sharon Kleyne. Every cell, system and structure ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... District , the only authorized OSHA Training Institute Education Center in Northern California, ... during the holiday season’s major sales events. As the volume of sales ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a ... the medical, research, and veterinary markets worldwide, announced today ... present at the 27 th Annual Piper Jaffray ... a.m. ET. The conference will be held at The ... City . Abaxis, Inc. is a ...
(Date:11/24/2015)... Edelris announce today that they have ... Poxel, CNRS, UCBL and ENS-Lyon on a new treatment to ... Hepatitis B virus (HBV) infection is a major public ... worldwide, 20 to 40% of them being at risk of ... existence of an effective preventive vaccine, the HBV infection is ...
(Date:11/24/2015)... MONROVIA, Calif. , Nov. 24, 2015 ... company developing engineered monoclonal antibodies for the treatment of ... announced that Bassil Dahiyat , Ph.D., president and ... in December: , 2015 Piper Jaffray Healthcare ... ET Location: New York, NY ...
Breaking Medicine Technology: